An Alumni of JLabs San Diego., Amydis Diagnostics, Inc. is structured around development of proprietary chemistry approaches for detection of amyloidgenic protein-associated diseases. The hallmark of many neurodegenerative diseases, -- Alzheimers, Parkinsons, Huntingtons, and Creutzfeldt-Jakobs disease - is an accumulation and deposition of amyloid plaques in the brain. A major challenge for diagnosing and monitoring the progression of amyloid-based diseases is the capability to distinguish deposits early in disease progression as well as between amyloid deposits of related origin but distinctly different, diseases. Non-invasive techniques that are not cost-prohibitive, convenient to administer and of a high degree of specificity and sensitivity that can discern early deposition and between different types of amyloids may offer important information necessary to develop effective treatment strategies that are tailored to specific diseases. Anchored in proprietary chemistry licensed out of UCSD using innovative approaches to detection of amyloid-related disorders. the firm was founded to address the urgent medical and clinical need for more sensitive and specific diagnostic testing for Alzheimers disease. By significantly improving the effectiveness, accessibility, and ease of testing, the technology has the potential to help physicians detect Alzheimers disease at its earliest stages. The firm is focused on a novel family of fluorescent probes to be used as diagnostic agents to image neurodegenerative diseases through an innovative ophthalmic approach.
